IN8bio, Inc.
INABNASDAQHealthcare● Active
$1.47
+$0.03(+2.08%)
Market Cap$6813890
P/E Ratio—
52W High$3.119
52W Low$1.17
IN8bio, Inc. (INAB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INAB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.26
Est. -$0.59 · +55.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
INAB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.34 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.59 | -$0.26 | +55.9% | — | — | — |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.18 | -$0.26 | -44.4% | — | $0.02B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$1.20 | -$0.85 | +29.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$1.50 | -$1.24 | +17.3% | — | — | — |
| ▼ Q2 FY2025 | May 7, 2025 | -$1.80 | -$2.10 | -16.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.07 | -$0.04 | +42.9% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.14 | -$0.15 | -7.1% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.34
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.26
EPS Est.
-$0.59
EPS Surpr.
+55.9%
Revenue
—
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.26
EPS Est.
-$0.18
EPS Surpr.
-44.4%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.85
EPS Est.
-$1.20
EPS Surpr.
+29.2%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$1.24
EPS Est.
-$1.50
EPS Surpr.
+17.3%
Revenue
—
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$2.10
EPS Est.
-$1.80
EPS Surpr.
-16.7%
Revenue
—
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.07
EPS Surpr.
+42.9%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.15
EPS Est.
-$0.14
EPS Surpr.
-7.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q3 FY2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q2 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q1 FY2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q4 FY2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2026 | $-0.34 | $-0.34 | $-0.34 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +55.9% | $1.58 | $1.60 | +1.27% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -44.4% | $1.99 | $1.91 | -4.02% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +29.2% | $1.63 | $1.66 | +1.84% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +17.3% | $2.10 | $2.15 | +2.38% |
| ▼ Q2 FY2025 | May 7, 2025 | -16.7% | $4.91 | $4.93 | +0.41% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +42.9% | $7.46 | $6.79 | -8.98% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -7.1% | $9.96 | $10.50 | +5.42% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -18.8% | $21.27 | $20.52 | -3.53% |
Q2 FY2026+1.27%
Report Date
May 7, 2026
EPS Beat/Miss
+55.9%
Price Before
$1.58
Price After
$1.60
Q1 FY2026-4.02%
Report Date
Mar 12, 2026
EPS Beat/Miss
-44.4%
Price Before
$1.99
Price After
$1.91
Q4 FY2025+1.84%
Report Date
Nov 6, 2025
EPS Beat/Miss
+29.2%
Price Before
$1.63
Price After
$1.66
Q3 FY2025+2.38%
Report Date
Aug 7, 2025
EPS Beat/Miss
+17.3%
Price Before
$2.10
Price After
$2.15
Q2 FY2025+0.41%
Report Date
May 7, 2025
EPS Beat/Miss
-16.7%
Price Before
$4.91
Price After
$4.93
Q1 FY2025-8.98%
Report Date
Mar 13, 2025
EPS Beat/Miss
+42.9%
Price Before
$7.46
Price After
$6.79
Q4 FY2024+5.42%
Report Date
Nov 12, 2024
EPS Beat/Miss
-7.1%
Price Before
$9.96
Price After
$10.50
Q3 FY2024-3.53%
Report Date
Aug 8, 2024
EPS Beat/Miss
-18.8%
Price Before
$21.27
Price After
$20.52
Avg Beat Reaction-0.87%
Avg Miss Reaction-0.43%
Beat Rate4 / 8 quarters
Largest Move-8.98% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INAB ends December
IN8bio, Inc. (INAB) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.26 — beating the analyst consensus of $-0.59 by +55.9%. The next INAB earnings date is expected around September 1, 2026.
Each quarter, investors track INAB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INAB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INAB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INAB earnings · 5 questionsIN8bio, Inc.'s next earnings report is expected around September 1, 2026. INAB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INAB historically reports after market close (AMC).
INAB earnings datewhen is INAB earningsINAB next earnings datewhen does INAB report earningsINAB earnings calendar
▸ Source: FMP · IN8bio, Inc. SEC filings · US GAAP · IN8bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026